News

Long-term Austedo Safely Leads to Reductions in Chorea: 3-year Data

Long-term treatment with Austedo (deutetrabenazine) safely led to sustained reductions in chorea for people with Huntington’s disease, including those who had switched from treatment with Xenazine (tetrabenazine). That’s according to about three years of follow-up data in the Phase 3 ARC-HD trial (NCT01897896), a study jointly conducted…

Enrollment Will Resume In Trial Of AMT-130 Gene Therapy

A data safety monitoring committee has recommended that enrollment of the highest dosing group resume in the European Phase 1/2 trial of AMT-130 in people with Huntington’s disease, but with additional safety measures in place. UniQure, the investigational treatment’s developer, announced in August that enrollment in…

2 Scientists Honored for Work in Huntington’s Disease, Treatments

The Hereditary Disease Foundation (HDF) is recognizing two scientists, Steven Finkbeiner and Natalia Barbosa, for their leadership in Huntington’s disease research. Both will speak at the organization’s 2022 Virtual Gala, set for Nov. 10 starting at 7 p.m. ET. The free, hourlong event will cover…

Palliative Care Training Can Help Clinicians With Tough Conversations

Palliative care training for all clinicians on an interdisciplinary team can increase the number of discussions about advanced care planning for people with Huntington’s disease, a new study shows. “To our knowledge, this is the first description of primary palliative care for Huntington’s disease in which all interdisciplinary team…

Teva Social Media Platforms Seek to Help HD Patients Manage Chorea

The pharmaceutical company Teva is turning to social media to help people with Huntington’s disease (HD) to improve the management of chorea — a hallmark motor symptom that an estimated 90% of patients with the neurodegenerative disorder will develop. The company, fully Teva Pharmaceutical Industries, has established…

Barriers to Multidisciplinary Care at Most US Huntington’s Clinics: Survey

Many U.S. clinics treating people with Huntington’s disease reported difficulties in accessing needed professionals — such as genetic counselors, social workers, and dietitians — to help provide multidisciplinary care to patients with the progressive disorder, according to a survey-based study. Researchers billed the study, which involved more than 150…